Literature DB >> 15205600

Non-allergic nature of docetaxel-induced acute hypersensitivity reactions.

A Ardavanis1, D Tryfonopoulos, I Yiotis, G Gerasimidis, N Baziotis, G Rigatos.   

Abstract

Based on observations of a discrepancy between 'hypersensitivity' reactions to docetaxel (DT) and the clinical features of allergic reactions, we explored the hypothesis that DT-induced acute hypersensitivity reactions (AHRs) have a non-allergic origin. Forty cancer patients receiving DT and 16 patients receiving other potentially allergenic chemotherapeutic agents were included in the study. All DT patients received standard pre- and post-medication. Before, during and after administration of the drugs, clinical symptoms and signs were recorded, and serial blood sampling was performed for the first 2 cycles for all patients or in all subsequent cycles in case of AHRs. Plasma histamine and serum tryptase, two established drug allergy markers, were measured. Seventy-five chemotherapy sessions were evaluable. Nine patients on DT, two on paclitaxel (PT) and one on pegylated doxorubicin experienced an AHR during the first course of chemotherapy. In all cases, heart rate remained stable or increased, while arterial pressure was unchanged or raised; no hypotension or bradycardia was noted. All episodes resolved with discontinuation of drug and did not reappear during a re-challenge with the same agent 30 min later. Tryptase levels were normal in all pre- and post-exposure samples (post-exposure: 11.32+/-35.63 microg/l, normal values <13.5 microg/l). In all but one AHR-free PT, pre- and post-exposure histamine concentrations remained normal (post-exposure: 2.86+/-11.88 nM, normal values <10 nM). No eosinophilia or basophilia was observed. We conclude that 'hypersensitivity' reactions to DT seem not to be histamine or tryptase mediated; thus, their allergenic nature should be questioned. The underlying mechanism may be related to other biological processes such as the release of vasoactive molecules or non-histamine/tryptase-mediated allergy. If the former is demonstrated by further study, the safety of DT administration will be confirmed, and the pre- and post-medication practice might be revisited.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205600     DOI: 10.1097/01.cad.0000131685.06390.b7

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  10 in total

Review 1.  Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators.

Authors:  Joana Caiado; Matthieu Picard
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

Review 2.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

3.  New cutaneous toxicities with generic docetaxel: are the excipients guilty?

Authors:  Margarita Garrido-Siles; Jose Javier Arenas-Villafranca; Elísabeth Pérez-Ruiz; M Francisca de Linares Fernández; Begoña Tortajada; Francisco Rivas-Ruiz; Vicente Faus; Antonio Rueda
Journal:  Support Care Cancer       Date:  2014-12-10       Impact factor: 3.603

4.  Perivascular carotid inflammation: an unusual case of carotidynia.

Authors:  Lama Azar; Harry D Fischer
Journal:  Rheumatol Int       Date:  2009-12-20       Impact factor: 2.631

5.  Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations.

Authors:  J Boulanger; J N Boursiquot; G Cournoyer; J Lemieux; M S Masse; K Almanric; M P Guay
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

6.  Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel.

Authors:  Rae Young Kang; Kyung Sook Yoo; Hyeon Ju Han; Ju-Yeun Lee; Se-Hoon Lee; Dong-Wan Kim; Yu Jeung Lee
Journal:  Support Care Cancer       Date:  2016-09-30       Impact factor: 3.603

7.  A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature.

Authors:  Patricia A Demoor; Yuri Matusov; Colleen Kelly; Shobha Kolan; Linda Barnachea; Lyudmila A Bazhenova
Journal:  J Cancer       Date:  2011-03-10       Impact factor: 4.207

Review 8.  Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.

Authors:  Brian A Baldo
Journal:  Oncoimmunology       Date:  2013-10-17       Impact factor: 8.110

Review 9.  Presentation and management of docetaxel-related adverse effects in patients with breast cancer.

Authors:  Maria Y Ho; John R Mackey
Journal:  Cancer Manag Res       Date:  2014-05-27       Impact factor: 3.989

10.  The Involvement of the RhoA/ROCK Signaling Pathway in Hypersensitivity Reactions Induced by Paclitaxel Injection.

Authors:  Chen Pan; Yu-Shi Zhang; Jia-Yin Han; Chun-Ying Li; Yan Yi; Yong Zhao; Lian-Mei Wang; Jing-Zhuo Tian; Su-Yan Liu; Gui-Qin Li; Xiao-Long Li; Zhong Xian; Ai-Hua Liang
Journal:  Int J Mol Sci       Date:  2019-10-09       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.